JLE

Médecine thérapeutique / Pédiatrie

MENU

Leucémie myéloïde chronique chez l’enfant, une pathologie rare et unique Volume 22, numéro 2, Avril-Mai-Juin 2019

  • [1] Hijiya N., Millot F., Suttorp M. Chronic myeloid leukemia in children : clinical findings, management, and unanswered questions. Pediatr Clin North Am. 2015;62:107-119. 1
  • [2] Hijiya N., Schultz K.R., Metzler M., Millot F., Suttorp M. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016;127:392-399. 4
  • [3] Gugliotta G., Castagnetti F., Apolinari M. First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: Current and emerging strategies. Drugs. 2014;74:627-643. 6
  • [4] Millot F., Maledon N., Guilhot J., Güneş A.M., Kalwak K., Suttorp M. Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia. Eur J Cancer. 2019;115:17-23.
  • [5] Hasford J., Baccarani M., Hoffmann V. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment : the EUTOS score. Blood. 2011;118:686-692. 3
  • [6] Hasford J., Pfirrmann M., Hehlmann R. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90:850-858. 11
  • [7] Sokal J.E., Gomez G.A., Baccarani M. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood. 1988;72:294-298. 1
  • [8] Gurrea Salas D., Glauche I., Tauer J.T., Thiede C., Suttorp M. Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients? Ann Hematol. 2015;94:1363-1371. 8
  • [9] Bansal D., Shava U., Varma N., Trehan A., Marwaha R.K. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer. 2012;59:481-484. 3
  • [10] Millot F., Guilhot J., Baruchel A. Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. Eur J Cancer. 2014;50:3206-3211. 18
  • [11] Castagnetti F., Gugliotta G., Baccarani M. Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol. 2015;26:185-192. 1
  • [12] Millot F., Traore P., Guilhot J. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics. 2005;116:140-143. 1
  • [13] Savage D.G., Szydlo R.M., Goldman J.M. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol. 1997;96:111-116. 1
  • [14] Arber D.A., Orazi A., Hasserjian R. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405. 20
  • [15] Suryanarayan K., Hunger S.P., Kohler S. Consistent involvement of the bcr gene by 9;22 breakpoints in pediatric acute leukemias. Blood. 1991;77:324-330. 2
  • [16] Krumbholz M., Karl M., Tauer J.T. Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia. Genes Chromosomes Cancer. 2012;51:1045-1053. 11
  • [17] Sokal J.E., Baccarani M., Tura S. Prognostic discrimination among younger patients with chronic granulocytic leukemia: Relevance to bone marrow transplantation. Blood. 1985;66:1352-1357. 6
  • [18] Millot F., Guilhot J., Suttorp M. Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents. Haematologica. 2017;102:1704-1708. 10
  • [19] Pfirrmann M., Baccarani M., Saussele S. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30:48-56. 1
  • [20] NCCN. NCCN clinical practices guidelines in oncology; chronic myelogenous leukemia, Version 1.2019. National Comprehensive Cancer Network. 2018.
  • [21] Gore L., Kearns P.R., de Martino M.L. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. J Clin Oncol. 2018;36:1330-1338. 13
  • [22] Hijiya N, et al. Efficacy and safety of nilotinib in pediatric patients with Philadelphia chromosome–positive (PH+) chronic myeloid leukemia (CML): Results from a phase 2 trial. Pediatr Blood Cancer 2017 ; 64 (S3). Abstract S22.
  • [23] Zwaan C.M., Rizzari C., Mechinaud F. Dasatinib in children and adolescents with relapsed or refractory leukemia : results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. J Clin Oncol. 2013;31:2460-2468. 19
  • [24] Champagne M.A., Fu C.H., Chang M. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2011;57:56-62. 1
  • [25] Millot F., Baruchel A., Guilhot J. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial. J Clin Oncol. 2011;29:2827-2832. 20
  • [26] Suttorp M., Schulze P., Glauche I. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: Results from a phase III trial. Leukemia. 2018;32:1657-1669. 7
  • [27] Cortes J.E., Saglio G., Kantarjian H.M. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016;34:2333-2340. 20
  • [28] Hochhaus A., Saglio G., Hughes T.P. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044-1054. 5
  • [29] de la Fuente J., Baruchel A., Biondi A. Managing children with chronic myeloid leukaemia (CML) : recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol. 2014;167:33-47. 1
  • [30] Soverini S., Hochhaus A., Nicolini F.E. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118:1208-1215. 5
  • [31] Nickel R.S., Daves M., Keller F. Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib. Pediatr Blood Cancer. 2015;62:2050-2051. 11
  • [32] Jaeger B.A., Tauer J.T., Ulmer A., Kuhlisch E., Roth H.J., Suttorp M. Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment. Med Sci Monit. 2012;18:CR721-CR728. 12
  • [33] Kroschwald L., Suttorp M., Tauer J.T., Zimmermann N., Günther C., Bauer A. Offtarget effect of imatinib and nilotinib on human vitamin D3 metabolism. Mol Med Rep. 2018;17:1382-1388. 1
  • [34] Narayanan K.R., Bansal D., Walia R. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis. Pediatr Blood Cancer. 2013;60:1148-1153. 7
  • [35] Samis J., Lee P., Zimmerman D., Arceci R.J., Suttorp M., Hijiya N. Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia. Pediatr Blood Cancer. 2016;63:1332-1338. 8
  • [36] Barber M.C., Mauro M.J., Moslehi J. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. Hematology Am Soc Hematol Educ Program. 2017;2017:110-114. 1
  • [37] Pallera A., Altman J.K., Berman E. NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1. 2017. J Natl Compr Canc Netw. 2016;14:1505-1512. 12
  • [38] Millot F., Claviez A., Leverger G., Corbaciglu S., Groll A.H., Suttorp M. Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase. Pediatr Blood Cancer. 2014;61:355-357. 2
  • [39] Marin D., Bazeos A., Mahon F.X. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381-2388. 14
  • [40] Efficace F., Rosti G., Aaronson N. Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica. 2014;99:788-793. 4
  • [41] Hughes T.P., Ross D.M. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128:17-23. 1
  • [42] Imagawa J., Tanaka H., Okada M. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): A multicentre phase 2 trial. Lancet Haematol. 2015;2:e528-e535. 12
  • [43] Ross D.M., Branford S., Seymour J.F. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study. Blood. 2013;122:515-522. 4
  • [44] Meyran DP, Guilhot J, Suttorp M, et al. Lymphoblastic predominance of blast phase in children with CML treated with imatinib, a report from the I-CML-Ped Study. ASH. 2015: Orlando.
  • [45] Hehlmann R., Saußele S., Voskanyan A., Silver R.T. Management of CML-blast crisis. Best Pract Res Clin Haematol. 2016;29:295-307. 3
  • [46] Jain P., Kantarjian H.M., Ghorab A. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017;123:4391-4402. 22
  • [47] Suttorp M., Claviez A., Bader P. Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: Results from the prospective trial CML-paed I. Klin Padiatr. 2009;221:351-357. 6
  • [48] Kondo T., Nagamura-Inoue T., Tojo A. Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia. Am J Hematol. 2017;92:902-908. 9
  • [49] Athale U., Hijiya N., Patterson B.C. Management of chronic myeloid leukemia in children and adolescents : Recommendations from the Children's Oncology Group CML Working Group. Pediatr Blood Cancer. 2019;66:e27827. 9
  • [50] Hijiya N., Suttorp M. How I treat chronic myeloid leukemia in children and adolescents. Blood. 2019;133:2374-2384. 22